[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]

Archive ouverte

Westeel, Virginie | Lebitasy, M. P. | Mercier, Mariette | Girard, Pascal | Barlesi, F. | Blanchon, F. | Tredaniel, J. | Bonnette, P. | Woronoff-Lemsi, M. C. | Breton, J. L. | Azarian, R. | Falcoz, P. E. | Friard, S. | Geriniere, L. | Laporte, S. | Lemarie, E. | Quoix, E. | Zalcman, G. | Guigay, J. | Morin, F. | Milleron, B. | Depierre, A. | Renseigné, Non

Edité par CCSD ; Elsevier Masson -

International audience. BACKGROUND: The authorities advocate a minimalist attitude towards the follow-up of resected bronchial carcinoma (clinical examination and chest x-ray). A survey showed that 70% of French respiratory physicians have chosen to use the CT scanner and often endoscopy. The published data are equivocal and are often based on retrospective studies. Lung cancer is a good model for a study of post-operative surveillance. Recurrences often occur in easily observed areas, they may be detected while still asymptomatic and are sometimes potentially curable. Second primary tumours may develop at the same site. METHODS: The Intergroupe Francophone de Cancerologie Thoracique (IFCT) has initiated a trial comparing simple follow-up (clinical examination, chest x-ray) with a more intensive follow-up (CT scan, fibreoptic bronchoscopy). The surveillance will take place every 6 months for 2 years and then annually until 5 years. EXPECTED RESULTS: The main aim is to determine whether intensive follow-up improves patient survival. The opposite question is equally important. If an expensive and demanding follow-up does not affect the chances of cure these results will influence our practice.

Consulter en ligne

Suggestions

Du même auteur

Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.

Archive ouverte | Westeel, Virginie | CCSD

International audience. In this phase II study, gemcitabine and vinorelbine were combined at suboptimal doses for weekly administration in advanced non-small cell lung cancer (NSCLC). The primary objectives were to ...

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

Archive ouverte | Quoix, E. | CCSD

International audience. There is no dedicated study on second-line treatment for elderly patients with advanced nonsmall cell lung cancer (NSCLC). We report the results on second-line erlotinib therapy from our prev...

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Archive ouverte | Peters, S. | CCSD

International audience

Chargement des enrichissements...